<DOC>
	<DOCNO>NCT02003365</DOCNO>
	<brief_summary>This study open-label , single administration design , conduct patient OA knee . Patients enrol sequentially 8 10 patient per Cohort follow : Cohort A : FX006 40 mg , Final Visit Week 20 Cohort B : FX006 40 mg , Final Visit Week 16 Cohort C : FX006 10 mg , Final Visit Week 12 Cohort D : FX006 40 mg , Final Visit Week 12 Cohort E : Triamcinolone acetonide immediate-release ( TCA IR ) 40 mg , Final Visit Week 12 Each patient evaluate 12 , 16 20 week follow single intra-articular ( IA ) injection FX006 10 mg 40 mg TCA IR 40 mg , depend assign Cohort . Following screen visit , safety evaluate three ( 3 ) out-patient visit synovial fluid collect Day 1 baseline measurement Final Visit drug concentration measurement .</brief_summary>
	<brief_title>Study Characterize Local Duration Exposure From FX006 Patients With Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Key Written consent participate study Willingness ability comply study procedure visit schedule ability follow verbal write instruction Has document diagnosis OA index knee make least 6 month prior Screening Currently meet American Collage Rheumatology Criteria ( clinical radiological ) OA Index knee pain &gt; 15 day last month Body mass index ( BMI ) â‰¤ 40 kg/m2 Ambulatory good general health Key History Reiter 's syndrome , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , arthritis associate inflammatory bowel disease , sarcoidosis amyloidosis History arthritides due crystal ( e.g. , gout , pseudogout ) History infection index joint Clinical sign symptom active knee infection crystal disease index knee Presence surgical hardware foreign body index knee Unstable joint ( torn anterior cruciate ligament ) within 12 month Screening IA corticosteroid ( investigational market ) joint within 6 month Screening IA hyaluronic acid ( investigational market ) index knee within 6 month Screening Oral corticosteroid ( investigational market ) within 1 month Screening Inhaled , intranasal topical corticosteroid ( investigational market ) within 2 week Screening Any IA investigational drug/biologic within 6 month Screening Prior use FX006 Prior arthroscopic open surgery index knee within 12 month Screening Planned/anticipated surgery index knee study period Active history malignancy within last 5 year , exception resect basal cell carcinoma , squamous cell carcinoma skin , resect cervical atypia carcinoma situ</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>knee</keyword>
	<keyword>steroid</keyword>
	<keyword>FX006</keyword>
	<keyword>triamcinolone acetonide</keyword>
	<keyword>synovial fluid</keyword>
</DOC>